Acute Lymphoblastic Leukemia (ALL)

First (CR1)/ Second Remission (CR2)
- Autologous or Allogeneic
  - CCT5001
    - Phase I
    - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Recurrent/Refractory B Cell Malignancies
    - PI: Milios
      - Stanford

First (CR1) of Higher Remission
- Haplo
  - BMT326
    - Phase III
    - Haploidentical HSCT & ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancy
    - PI: Johnson
      - Pending

High Risk First (CR1) Remission
- Allogeneic
  - BMT333
    - Phase III
    - Transplantation of NiCord vs Unmanipulated Umbilical/Cord Blood in Hematological Malignancies
    - PI: Rezvani
      - Pending

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu